Boehringer Ingelheim

News

Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.

News

Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?

News

Pharma is embracing DTC selling of medicines in the US, and industry body PhRMA has stepped in to help cut out the middlemen in the supply chain.

R&D

In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.

News

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for lung cancer therapy Hernexeos.

News

Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.